CIRM Funded Clinical Trials

Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies

Disease Area:
B cell cancers, Leukemia
CIRM Grant:
CLIN2-10846 (Closed)
Award Value:
Trial Sponsor:
Stanford University
Trial Stage:
Phase 1
Trial Status:
Active, not recruiting
Targeted Enrollment:
56 ID:


Chimeric Antigen Receptor (CAR) T Cell Therapy is an innovative cancer therapy with very encouraging response rates in patients. The therapy works by isolating a patient’s own T cells (a type of immune cell) and then genetically engineering them to recognize a protein on the surface of cancer cells, triggering their destruction. In some patients with B cell leukemias, however, cancer cells escape detection by the modified T cells and cause the cancer’s reoccurrence.

Researchers at the Stanford University School of Medicine have developed an engineered T cell designed to recognize not one, but two, cell surface proteins on cancer cells with the aim of enhancing a patient’s response to the therapy and reducing the potential for relapse. In addition, some of the T cells will form memory stem cells that will survive for years and continue to survey the body, killing any new or surviving cancer cells.


Open label, dose escalation study.


Safety and feasibility.

News about this clinical trial:

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website